Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMVOY6B)

• Drug Name: AMD-070 Drug Info
• Synonyms: AMD 070; AMD070; AMD11070; S14-0353; N-(1H-benzoimidazol-2-ylmethyl)-N-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine; N'-(1H-Benzo[d]imidazol-2-ylmethyl)-N'-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine Trihydrobromide Dihydrate

Indication

Disease Entry	ICD 11	Status	REF
Whim syndrome	4A00.Y	Phase 3	[1]
Human immunodeficiency virus infection	1C62	Phase 1/2	[2]
Melanoma	2C30	Phase 1/2	[3]
Merkel cell carcinoma	2C34	Phase 1/2	[3]
Renal cell carcinoma	2C90	Phase 1/2	[3]
Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[3]

• Cross-matching ID:
  PubChem CID: 11256587
  ChEBI ID: CHEBI:138865
  CAS Number: CAS 558447-26-0
  TTD Drug ID: DMVOY6B

Molecule-Related Drug Atlas

Drug(s) Targeting C-X-C chemokine receptor type 4 (CXCR4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Plerixafor	DMCJN1P	Non-hodgkin lymphoma	2B33.5	Approved	[5]
Motixafortide	DMW34B1	Multiple myeloma	2A83	Approved	[6]
Ulocuplumab	DM6PMNR	Multiple myeloma	2A83	Phase 3	[7]
Balixafortide	DMUOFAC	Metastatic breast cancer	2C6Y	Phase 3	[8]
TG-0054	DM2ZLWH	Macular degeneration	9B78.3	Phase 2	[9]
POL-6326	DM4OT29	Human immunodeficiency virus infection	1C62	Phase 2	[10]
CTCE-9908	DM95XR8	Sarcoma	2A60-2C35	Phase 1/2	[11]
USL311	DM6HPEC	Recurring respiratory infection	CA07-CA45	Phase 1/2	[3]
GMI-1359	DML1KSA	Breast cancer	2C60-2C65	Phase 1	[12]
ALX-0651	DMIRYM8	Haematological malignancy	2B33.Y	Phase 1	[13]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
C-X-C chemokine receptor type 4 (CXCR4)	TTBID49	CXCR4_HUMAN	Antagonist	[4]

References

• [1] ClinicalTrials.gov (NCT03995108) Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome. U.S. National Institutes of Health.
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8580).
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Pharmacokinetic effect of AMD070, an Oral CXCR4 antagonist, on CYP3A4 and CYP2D6 substrates midazolam and dextromethorphan in healthy volunteers. J Acquir Immune Defic Syndr. 2008 Apr 15;47(5):559-65.
• [5] Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
• [6] The CXCR4 Antagonist BL-8040 Efficiently Induces Apoptosis and Inhibits The Survival Of AML Cells. November 15, 2013; Blood: 122 (21).
• [7] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [8] Anti-ageing pipeline starts to mature.Nat Rev Drug Discov. 2018 Sep;17(9):609-612.
• [9] CXCR4 Antagonist TG-0054 Mobilizes Mesenchymal Stem Cells, Attenuates Inflammation, and Preserves Cardiac Systolic Function in a Porcine Model of Myocardial Infarction. Cell Transplant. 2015;24(7):1313-28.
• [10] CXCR4 inhibitors: tumor vasculature and therapeutic challenges. Recent Pat Anticancer Drug Discov. 2012 Sep;7(3):251-64.
• [11] A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer. J Surg Res. 2009 Aug;155(2):231-6.
• [12] Clinical pipeline report, company report or official report of GlycoMimetics.
• [13] Therapeutic antibodies directed at G protein-coupled receptors. MAbs. 2010 Nov-Dec; 2(6): 594-606.